Bazedoxifene acetate; estrogens, conjugated
Bazedoxifene acetate; estrogens, conjugated: 1 brand, 0 generics; first approved Oct 03, 2013; on patent until Mar 10, 2027.
Protected until Mar 10, 2027 (earliest listed patent expiry).
Brand (NDA) products
- WYETH PHARMSNDA 0222472013
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 20MG BASE;0.45MG TABLET ORAL Rx -
Patent & exclusivity timeline
Listed patents
| Patent | Expires | In | Type |
|---|---|---|---|
| 7683051 | in 5 mo | SubstanceProductU-594 |
Approval history
All 1 application were approved in 2013.
Bazedoxifene acetate; estrogens, conjugated: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Bazedoxifene acetate; estrogens, conjugated
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo